To investigate the role of LUCAT1 in promoting cancer stem cell characteristics and HNSCC progression, highlighting its potential as a therapeutic target through its interaction with miR-128.
Key Findings:
Knockdown of LUCAT1 significantly reduces cancer cell stemness and suppresses HNSCC progression, indicating its potential as a therapeutic target.
LUCAT1 acts as a ceRNA, sponging miR-128 and promoting oncogenesis by relieving post-transcriptional repression of downstream targets, which may inform future treatment strategies.
Restoration of miR-128 reverses the antitumor efficacy of LUCAT1 knockdown in HNSCC cells, highlighting the importance of this regulatory axis.
BMI1 is identified as a direct target of miR-128 in HNSCC cells, suggesting a specific pathway for intervention.
Interpretation:
LUCAT1 is a key regulatory component in the cancer stemness network of HNSCC, influencing stem cell-like traits and malignant progression through the LUCAT1/miR-128 axis, which may serve as a promising therapeutic target.
Limitations:
The clinical relevance and prognostic value of the LUCAT1/miR-128/BMI1 axis require further validation in patient cohorts, and potential confounding factors in the study should be addressed.
Conclusion:
The study highlights the potential of targeting the LUCAT1/miR-128 axis as a therapeutic strategy for HNSCC.
